Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder.

Journal Article (Clinical Trial;Journal Article)

OBJECTIVE: To develop effect sizes for 3 mood stabilizers--lithium, divalproex sodium, and carbamazepine--for the acute-phase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years. METHOD: Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly Clinical Global Impression Improvement scores and the Young Mania Rating Scale (Y-MRS). RESULTS: Using a > or = 50% change from baseline to exit in the Y-MRS scores to define response, the effect size was 1.63 for divalproex sodium, 1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were as follows: sodium divalproex, 53%; lithium, 38%; and carbamazepine, 38% (chi 2(2) = 0.85, p = .60). All 3 mood stabilizers were well tolerated, and no serious adverse effects were seen. CONCLUSIONS: Divalproex sodium, lithium, and carbamazepine all showed a large effect size in the open treatment of children and adolescents with bipolar I or II disorder in a mixed or manic episode.

Full Text

Duke Authors

Cited Authors

  • Kowatch, RA; Suppes, T; Carmody, TJ; Bucci, JP; Hume, JH; Kromelis, M; Emslie, GJ; Weinberg, WA; Rush, AJ

Published Date

  • June 2000

Published In

Volume / Issue

  • 39 / 6

Start / End Page

  • 713 - 720

PubMed ID

  • 10846305

International Standard Serial Number (ISSN)

  • 0890-8567

Digital Object Identifier (DOI)

  • 10.1097/00004583-200006000-00009

Language

  • eng

Conference Location

  • United States